GlycoEra AG Email Format

Biotechnology ResearchZurich, Switzerland11-50 Employees

GlycoEra AG is a Swiss biotechnology company focused on developing biologics that aim to remove circulating proteins implicated in autoimmune diseases, such as autoantibodies. The approach seeks rapid and selective degradation of these targets while avoiding broad immunosuppression, with potential benefits in safety and the possibility of earlier disease intervention. Its BiND platform (Biologic Natural Degrader) is described as capable of degrading circulating proteins of interest across therapeutic areas, including autoantibodies, inflammatory factors, and protein aggregates in neurological disease. GlycoEra is based in Wädenswil, near Zurich, and operates within the biotechnology research sector with a small to mid-sized team. In January 2026, the company announced the appointment of Petra Duda, M.D., Ph.D., as Chief Medical Officer.

Sign up for free to view info

Company overview Employee directory